Maribavir

3 trials 1 recruiting JAnti-infectives Orphan designation

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

1 Recruiting

1 Completed trials

3 Sponsors

5 Countries

Phase III

Phase II

Phase IV

Phase III: 1 Phase II: 1 Phase IV: 1

Oversight events:

4 temporary halts across 1 trial

View oversight register →

Indications tested

Cytomegalovirus infection 1

Sponsors using this IMP

Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca 1 Gruppo Italiano Per Il Trapianto Di Midollo Osseo Cellule Staminali Emopoietiche E Terapia Cellulare 1 Takeda Development Center Americas Inc. 1

All trials

3 total

Phase IV study to evaluate the safety and efficacy of maribavir in reducing Epstein–Barr virus in young adult kidney transplant recipients. Pending

2025-524786-25-00 Phase IV 1 country Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca
A phase 2, multicentric study to assess the efficacy and safety of maribavir treatment in hematopoietic stem cell transplant (HSCT) recipien… Recruiting

2025-521074-34-00 Phase II 1 country Gruppo Italiano Per Il Trapianto Di Midollo Osseo Cellule Staminali Emopoietiche…
A study to test the safety, dosage and effectiveness of maribavir for the treatment of cytomegalovirus (CMV) infection in children and adole… Ended

2023-508988-73-00 Phase III 4 countries Takeda Development Center Americas Inc.

Showing 1–3 of 3 trials

← All drugs A–Z